A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Abrilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Amgen
- 02 Feb 2017 Planned End Date changed from 1 Nov 2019 to 1 Apr 2018.
- 29 May 2016 This trial has been terminated in Denmark.
- 03 Mar 2016 Planned End Date changed from 1 Mar 2019 to 1 Nov 2019, as reported by ClinicalTrials.gov.